Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
By Clark D Russell, Jonathan E Millar, J. Baillie. The Lancet, 2020
1,869 citations recorded by the source corpus.
The 2019 novel coronavirus (2019-nCoV) outbreak is a major challenge for clinicians. The clinical course of patients remains to be fully characterised, little data are available that describe the disease pathogenesis, and no pharmacological therapies of proven efficacy yet exist. Corticosteroids were widely used during the outbreaks of severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, and are being used in patients with 2019-nCoV in addition to other therapeutics. However, current interim guidance from WHO on clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected (released Jan 28, 2020) advises against the use of corticosteroids unless indicated for another reason. Understanding the evidence for harm or benefit from corticosteroids in 2019-nCoV is of immediate clinical importance. Here we discuss the clinical outcomes of corticosteroid use in coronavirus and similar outbreaks (table). Acute lung injury and acute respiratory distress syndrome are partly caused by host immune responses. Corticosteroids suppress lung inflammation but also inhibit immune responses and pathogen clearance. In SARS-CoV infection, as with influenza, systemic inflammation is associated with adverse outcomes. In SARS, inflammation persists after viral clearance. Pulmonary histology in both SARS and MERS infections reveals inflammation and diffuse alveolar damage, with one report suggesting haemophagocytosis. Theoretically, corticosteroid treatment could have a role to suppress lung inflammation. In a retrospective observational study reporting on 309 adults who were critically ill with MERS, almost half of patients (151 [49%]) were given corticosteroids (median hydrocortisone equivalent dose [ie, methylprednisolone 1:5, dexamethasone 1:25, prednisolone 1:4] of 300 mg/day). Patients who were given corticosteroids were more likely to require mechanical ventilation, vasopressors, and renal replacement therapy. After statistical adjustment for immortal time and indication biases, the authors concluded that administration of corticosteroids was not associated with a difference in 90-day mortality (adjusted odds ratio 0·8, 95% CI 0·5–1·1; p=0·12) but was associated with delayed clearance of viral RNA from respiratory tract secretions (adjusted hazard ratio 0·4, 95% CI 0·2–0·7; p=0·0005). However, these effect estimates have a high risk of error due to the probable presence of unmeasured confounders. In a meta-analysis of corticosteroid use in patients with SARS, only four studies provided conclusive data, all indicating harm. The first was a case-control study of SARS patients with (n=15) and without (n=30) SARS-related psychosis; all were given corticosteroid treatment, but those who developed psychosis were given a higher cumulative dose than those who did not (10 975 mg hydrocortisone equivalent vs 6780 mg; p=0·017). The second was a randomised controlled trial of 16 patients with SARS who were not critically ill; the nine patients who were given hydrocortisone (mean 4·8 days [95% CI 4·1–5·5] since fever onset) had greater viraemia in the second and third weeks after infection than those who were given 0·9% saline control. The
Subfields: Infectious Diseases, Neurology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/634157799e6d0bbfb0fb50dd054e8bf239fd0814
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Dexamethasone in Hospitalized Patients with Covid-19 (2021, background): “Invasive mechanical ventilation 324 (15) 683 (16) NA NA 1007 (100)”
- Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review (2020, background): “, exacerbation of chronic obstructive pulmonary disease) [40,41].”
- Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak (2020, background): “org with lung cancer could contribute to the worse outcome in this subpopulation (15, 16).”
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, neutral): “However, their use in managing SARS-CoV-2 patients is currently highly contested [169] [170] [171] .”
- Kidney disease is associated with in-hospital death of patients with COVID-19 (2020, background): “The difference in the use of glucocorticoids may be explained by the condition of patients with AKI that was more severe, thus physicians tended to use glucocorticoids in the most critically ill patients, even if there is a controversy on the use of glucocorticoids in patients with COVID-19.(22,23)”
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. (2020, methodology): “Risk of bias assessments were based on the trial protocols and flowcharts following the Consolidated Standards of Reporting Trials together with this information supplied by the investigators of each trial: (1) the methods used to generate the allocation sequence and conceal randomized allocation; (”
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? (2020, critical): “Several studies even reported inferior outcomes of SARS patients treated with corticosteroids [16].”
- A Review of Coronavirus Disease-2019 (COVID-19) (2020, neutral): “The role of corticosteroids drugs is not clear; while current international agreement and WHO advocate are against their use, Chinese authority give permission to use short term therapy with low-to-moderate dose of corticosteroids in COVID-19 patients [24, 25].”
- The Novel Coronavirus 2019 epidemic and kidneys (2020, neutral): “Therefore, the use of steroids is controversial and not recommended by the World Health Organization because of potential inhibition of viral clearance and prolongation of the duration of viremia.(28)”
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease (2020, background): “If a MAS-like state exists and excessive IL-6 levels are detrimentalwhy shouldn't corticosteroids be first line therapy as these will vigerously suppress IL-6 and a raft of other cytokines? Although the recent open label study from Wu and colleagues showed a benefit for corticosteroids, the consensu”
- Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report (2020, background): “Several therapeutic interventions to mitigate inflammatory organ injury have been proposed in viral pneumonia but the value of corticosteroids has been widely debated.(17,18)”
- Proteomic and Metabolomic Characterization of COVID-19 Patient Sera (2020, background): “, 2018), but showed 339 negligible effect on COVID-19 patients and may even have induced lung 340 injury (Russell et al., 2020).”